Reading on clinical trial dot gov, it looks like 45 mg was the only dosing option for EPIC, a trial in first line CML. Increasing the Imatinib dosing was permitted. Scuttling the trial as it stood was probably necessary, It looks like lower doses of ponatinib weren't an option.
Lower doses weren't an option for that trial Starting over may not be an option either as it may prove too expensive. Meanwhile the buzzards are circling. They have over $300mm net in the kitty but they are going to need it just to survive. I took my medicine this morning in the pre-market. Pity...the drug actually does work and there is a pretty obvious pathway to utilizing it appropriately, i.e. reduce the dose and screen the patient population for previous stroke and cardiac events. That's where they will likely end up but it's going to be very expensive and time consuming getting there.